Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study.
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet MMF, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, Andre M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens M, Griolet S, Gaulard P, Delfau-Larue MH, de Leval LL, Damaj GL.
Tournilhac O, et al. Among authors: hacini m.
Blood Adv. 2025 Aug 4:bloodadvances.2024015787. doi: 10.1182/bloodadvances.2024015787. Online ahead of print.
Blood Adv. 2025.
PMID: 40758949